NCT03683810

The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia

The Effectiveness of Lactoferrin in the Management of Treatment-induced Anemia in Hematological Patients

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Cyprus University of Technology · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This will be a randomised control trial designed to test the effectiveness of lactoferrin in the management of treatment-induced anemia in patients with hematological malignancies.

Detailed description

Chemotherapy induced anemia (CIA) is a common adverse event in cancer patients reported to occur in 20-60% whilst the resulting low hemoglobin level is associated with impaired quality of life. Lactoferrin (LF) is a non-haem iron-binding protein that is part of the transferrin protein family, along with serum transferrin, ovotransferrin, melanotransferrin and the inhibitor of carbonic anhydrase, whose function is to transport iron in blood serum. The aim of the study is to test the effectiveness of LF along with standard care in the management of treatment-induced anemia.

Conditions

• Anemia

Interventions

Type	Name	Description
DIETARY_SUPPLEMENT	Lactoferrin	Lactoferrin in tablets 4g/daily
DRUG	Recombinant human erythropoietin	Recombinant human erythropoietin (rHuEPO, epoetin alfa)

Timeline

• Start date: 2019-01-14
• Primary completion: 2023-01-01
• Completion: 2023-06-01
• First posted: 2018-09-25
• Last updated: 2022-09-06

Locations

2 sites across 1 country: Cyprus